

Genome-scale metabolic reconstructions of multiple *Escherichia coli* strains highlight strain-specific adaptations to nutritional environments

Jonathan M. Monk^a, Pep Charusanti^b, Ramy K. Aziz^{b,c}, Joshua A. Lerman^d, Ned Premyodhin^b, Jeffrey D. Orth^{b,1}, Adam M. Feist^{b,2}, and Bernhard Ø. Palsson^{b,d,2}

Department of ^aNanoEngineering and ^bBioengineering and ^dProgram in Bioinformatics, University of California, San Diego, La Jolla, CA 92093; and ^cDepartment of Microbiology and Immunology, Faculty of Pharmacy, Cairo University, 11562 Cairo, Egypt

Edited by Amy A. Caudy, University of Toronto, Toronto, Canada, and accepted by the Editorial Board October 18, 2013 (received for review April 26, 2013)

Genome-scale models (GEMs) of metabolism were constructed for 55 fully sequenced *Escherichia coli* and *Shigella* strains. The GEMs enable a systems approach to characterizing the pan and core metabolic capabilities of the *E. coli* species. The majority of pan metabolic content was found to consist of alternate catabolic pathways for unique nutrient sources. The GEMs were then used to systematically analyze growth capabilities in more than 650 different growth-supporting environments. The results show that unique strain-specific metabolic capabilities correspond to pathotypes and environmental niches. Twelve of the GEMs were used to predict growth on six differentiating nutrients, and the predictions were found to agree with 80% of experimental outcomes. Additionally, GEMs were used to predict strain-specific auxotrophies. Twelve of the strains modeled were predicted to be auxotrophic for vitamins niacin (vitamin B₃), thiamin (vitamin B₁), or folate (vitamin B₉). Six of the strains modeled have lost biosynthetic pathways for essential amino acids methionine, tryptophan, or leucine. Genome-scale analysis of multiple strains of a species can thus be used to define the metabolic essence of a microbial species and delineate growth differences that shed light on the adaptation process to a particular microenvironment.

systems biology | mathematical modeling | core and pan genome

Over the last decade, the *Escherichia coli* K-12 MG1655 strain has been used extensively as a model organism for research on microbial metabolic systems biology. However, the increasing availability of genomic sequences for other *E. coli* strains suggests that this nonpathogenic laboratory strain's genes are a small part of the genomic diversity in the *E. coli* species. For instance, the *E. coli* O157:H7 EDL933 strain responsible for worldwide outbreaks of hemorrhagic colitis has one million more base pairs of DNA than K-12 MG1655 (~20% larger) (1–3). Multiple genomic sequences have defined a set of genes that is common to all *E. coli* strains (i.e., a “core” genome), and it has been determined that they represent a small fraction of the entire *E. coli* gene pool. The growing availability of whole genome sequences for *E. coli* strains thus brings into focus the question: what is a strain and what is a species?

A recent study of 20 *E. coli* strains found that a large fraction of the shared genomic elements with known function are related to metabolism (4). Therefore, it is important to characterize the genes that encode a core set of metabolic capabilities to understand their effect on cellular functions, as they constitute a common denominator that can be used to define the core metabolic potential of the *E. coli* species. Metabolic network reconstructions have proven to be powerful tools to probe the genomic diversity of metabolism between organisms (5–10). As useful as genome annotation is, it does not provide an understanding of the integrated function of gene products to produce phenotypic states. K-12 MG1655 was the first *E. coli* strain to have its genome entirely sequenced (11). A first genome-scale metabolic reconstruction was completed for this strain 3 y later

(12). Since then, the reconstruction of MG1655 has undergone a series of expansions in the intervening 13 y as more information about the genome and its annotation has become available (13–15). The most recent reconstruction, iJO1366 (15), accounts for 1,366 genes (39% of functionally annotated genes on the genome) and their gene products. The genome-scale metabolic reconstruction for *E. coli* K-12 MG1655 is the most complete metabolic reconstruction available to date (16, 17). However, as more *E. coli* genomic sequences have become available, it has become clear that *E. coli* K-12 MG1655 only partially represents the *E. coli* species. Thus, it is important to construct genome-scale models (GEMs) for other *E. coli* strains because of this species' importance to human health, basic microbiological science, and industrial biotechnology (18).

The goal of this study was to construct GEMs for all *E. coli* strains with fully sequenced genomes and thus to reconstruct the metabolic network for an entire species and its strain-specific variants. *Shigella* strains were included on the basis of 16S ribosomal profiling experiments that classify *Shigella* strains as members of the *E. coli* species (19), despite the historical distinction of having their own genus. Therefore, the formulated GEMs span commensal strains, as well as both intestinal and extraintestinal pathogenic strains of *E. coli*, allowing for a comprehensive analysis of the representative metabolic capabilities of the *E. coli* species.

Significance

Multiple *Escherichia coli* genome sequences have recently been made available by advances in DNA sequencing. Analysis of these genomes has demonstrated that the fraction of genes common to all *E. coli* strains in the species represents a small fraction of the entire *E. coli* gene pool. This observation raises the question: what is a strain and what is a species? In this study, genome-scale metabolic reconstructions of multiple *E. coli* strains are used to reconstruct the metabolic network for an entire species and its strain-specific variants. The models are used to determine functional differences between strains and define the *E. coli* species based on common metabolic capabilities. Individual strains were differentiated based on niche-specific growth capabilities.

Author contributions: J.M.M., J.A.L., A.M.F., and B.Ø.P. designed research; J.M.M., P.C., R.K.A., and N.P. performed research; J.M.M., P.C., R.K.A., J.A.L., N.P., J.D.O., and A.M.F. analyzed data; and J.M.M., P.C., N.P., A.M.F., and B.Ø.P. wrote the paper.

The authors declare no conflict of interest.

This article is a PNAS Direct Submission. A.A.C. is a guest editor invited by the Editorial Board.

Freely available online through the PNAS open access option.

¹Present address: Cell Systems Informatics, Intrexon Corporation, San Carlos, CA 94070.

²To whom correspondence may be addressed. E-mail: afeist@ucsd.edu or palsson@ucsd.edu.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1307797110/-DCSupplemental.

Results

Characteristics of *E. coli* Core and Pan Metabolic Content. A set of 55 *E. coli* genome-scale reconstructions was built and used to compare gene, reaction, and metabolite content between strains (Datasets S1 and S2). The content shared among all reconstructions thereby defines the core metabolic capabilities among all of the strains. Similarly, the metabolic capabilities of all of the strains were combined to define the full set that encompasses all models and thereby define the “pan” metabolic capabilities among all of the strains. By analogy to mathematical set theory, the core metabolic content is the intersection of the gene, reaction, and metabolite content of all 55 models, whereas the pan metabolic content is the union of these features among the models (Fig. 1A).

The size and content of the core metabolic content characterizes the metabolic foundation of *E. coli* as a species. The core model has 965 metabolic genes that catalyze 1,773 reactions using 1,665 metabolites. The most highly conserved subsystems were lipid metabolism, cell wall, membrane and envelope metabolism, nucleotide metabolism, and cofactor and prosthetic group metabolism. Reactions involved in lipid metabolism, cell wall/membrane/envelope metabolism, and cofactor and prosthetic group biosynthesis were highly represented (>80%) in the core reactome. Most of these reactions synthesize essential components such as vitamins and cofactors like riboflavin, Coenzyme A, and biotin, as well as quinones and isoprenoids. In contrast, only 36% of carbohydrate metabolism reactions were part of the core reactome. These reactions were comprised of central metabolism reactions including anaplerotic reactions, the citric acid cycle, glycolysis/gluconeogenesis, and the pentose phosphate pathway.

The pan metabolic capabilities are comprised of the total number of different reactions found in all strains and are thus an indicator of the full metabolic capabilities within a species. The *E. coli* pan reconstruction content contains 1,460 metabolic genes, 2,501 reactions, and 2,043 metabolites. About 64% of reactions in carbohydrate metabolism were part of the pan reactome, the largest group (Fig. 1B). A majority of these reactions are involved in alternate carbon source metabolism. Cell wall and membrane envelope metabolism accounted for 18% of reactions in the pan reactome. These reactions account for a major phenotypic distinction between *E. coli* strain’s serogroup, in particular the O antigen (20). Also, 30% of amino acid metabolism reactions are part of the pan reactome.

Ability to Catabolize Different Nutrient Sources Distinguishes Metabolic Models of *E. coli* Strains. The conversion of static metabolic network reconstructions into computable mathematical models allows computation of phenotypes based on the content of each reconstruction. Thus, the 55 strain-specific reconstructed networks were converted into GEMs that allow for the simulation of phenotype

(21). This set of GEMs allows for a meaningful interpretation of the content of each reconstruction and allows for the prediction of a strain’s microenvironmental and ecological niche.

Reactions belonging to the alternate carbon metabolism subsystem made up the majority of reactions in the pan reactome (Fig. 1B). Thus, it was hypothesized that these capabilities may reflect functional differences in the ability of different strains of *E. coli* to adapt to different nutritional environments. To test this hypothesis, growth was simulated in silico for all 55 *E. coli* and *Shigella* GEMs on minimal media in 654 growth conditions. The conditions were composed of all sole growth supporting carbon, nitrogen, phosphorous, and sulfur sources in both aerobic and anaerobic environments (Fig. 2 and Dataset S1).

In contrast to the *E. coli* GEMs, the *Shigella* GEMs displayed a large loss of catabolic capabilities across the 654 growth conditions. This computational result supports evidence showing that *Shigella* strains have lost catabolic pathways for many nutrient sources (22). Models of *Shigella* strains completely lost the capability to sustain growth on nutrient sources for which more than 90% of *E. coli* models had growth capabilities. Some of these nutrients include D-alantoin, D-malate, and xanthine as carbon sources, as well as inosine as a nitrogen source. Furthermore, only one of the eight *Shigella* strain models (13%) was able to sustain growth on choline or L-fucose, two carbon sources that most *E. coli* strain models examined were predicted to catabolize.

Set of Substrates Differentiate Pathogenic Strains from Commensal (Nonpathogenic) Strains. Based on simulated growth phenotypes, we observed a general separation of commensal strains from both extraintestinal pathogenic *E. coli* (ExPec) and intestinal pathogenic *E. coli* (InPec) strains of *E. coli*, suggesting that a classification schema of strains based on metabolic capabilities is possible (Fig. 3). Common laboratory strains of *E. coli* such as *E. coli* K-12 MG1655 are nonpathogenic, commensal strains. As a first step toward establishing such a schema, the separation between ExPec and commensal strain models was examined. A Fisher’s exact test was used to establish that models of ExPec strains exhibited a statistically significant capability to catabolize four unique compounds with $P < 0.05$ (Table 1).

Most models of strains widely regarded as safe laboratory strains such as K-12 strains, BW2952, and DH1 were unable to grow on a unique subset of nutrients. Notably, *N*-acetyl-D-galactosamine supported growth in 100% of ExPec strain models compared with 67% of commensal strain models ($P = 3.9 \times 10^{-2}$). Additionally, several commensal strain models exhibited a statistically significant overrepresentation of catabolic pathways for 13 nutrient sources (Table 1). For example, fructoselysine and psicoselysine share the same catabolic pathway and were not catabolizable by any of the ExPec models; however, 89% ($P = 2.2 \times 10^{-6}$) of the intestinal strain models could use fructoselysine or psicoselysine as a sole carbon source. Fructoselysine is poorly digested in the human small intestine, and little is excreted, hinting that the majority of dietary fructoselysine may be digested by the intestinal microbiota (23). Further, 4-hydroxyphenylacetate, an aromatic compound, was catabolized as a sole carbon source for 55% of commensal strain models compared with only 9% of ExPec strain models ($P = 1.3 \times 10^{-2}$). Hydroxyphenylacetic acids are produced by bacterial fermentation of short chain peptides and amino acids in the human large intestine (24). 4-Hydroxyphenylacetate undergoes eight different enzymatic reactions before being converted to pyruvate and succinate-semialdehyde that can then be converted to succinate and enter the tricarboxylic acid cycle (25).

Next, the models of strains known to reside intestinally were compared to investigate differences between commensal and InPec strains. Models of InPec strains displayed an advantage in their ability to support growth on seven unique carbon and nitrogen sources (Table 2). Some of the substrates had unique enrichment specifically among the enterohemorrhagic (EHEC) strains, responsible for worldwide cases of diarrhea and hemolytic uremic syndrome (HUS) (26). Sucrose supported growth for 65% of the InPec strains including 100% of EHEC strains




Fig. 1. Core and pan metabolic capabilities of the *E. coli* species. The core and pan metabolic content was determined for genome-scale metabolic models (GEMs) of 55 unique *E. coli* strains. (A) The core content, illustrated by the intersection of the Venn diagram, is shared with all strains. The pan content consists of all content in any model and includes the core content. The Venn diagram is not to scale. (B) Classification of reactions in the core and pan reactomes by metabolic subsystem.




Fig. 2. Clustering of species by unique growth-supporting conditions. Predicted metabolic phenotypes on the variable growth-supporting nutrient conditions composed of different carbon, nitrogen, phosphorous, and sulfur nutrient sources in aerobic and anaerobic conditions. Rows represent individual strains, and columns represent different nutrient conditions. In general, strains clustered into their respective pathotypes of commensal *E. coli* strains, intestinal pathogenic *E. coli* strains, extra-intestinal pathogenic *E. coli* strains, and *Shigella* strains. An asterisk symbol indicates those strains that clustered outside of their respective pathotype. All growth conditions are listed in Dataset S1.

compared with only 33% of commensal strains ($P = 5.0 \times 10^{-2}$). Also, consistent with other reports (27), urease activity was present in EHEC strain models only. Urea supported growth as a sole nitrogen source for 47% of InPec strain models, including 100% of the EHEC models compared with 0% of commensal strain models ($P = 1.0 \times 10^{-3}$). Urease degrades urea into CO_2 and NH_4 and therefore may provide an additional source of nitrogen for cells in nitrogen-limited environments.

In contrast to InPec strains, commensal strains displayed an advantage in their ability to degrade 11 unique carbon and nitrogen

sources (Table 2). The short chain fatty acids (SCFAs) acetoacetate and butyrate were found to support growth as sole carbon sources for 78% of commensal strain models compared with 47% of InPec models ($P = 5.0 \times 10^{-2}$). Notably, none of the EHEC strain models were able to catabolize either of these two compounds, and only 13% of *Shigella* models were able to use them as a sole source of carbon.

Metabolic Models Combined with Gap-Filling Methods Facilitate Investigation into the Genetic Basis of Strain-Specific Auxotrophies.

In addition to investigating growth-supporting nutrients, GEMs can also be used to examine the genetic bases of strain-specific auxotrophies. Twelve of the 55 reconstructed GEMs were unable to generate essential biomass components from glucose M9 minimal media without addition of growth-supporting compounds to the in silico media. The SMILEY algorithm, a method to fill gaps in metabolic networks (28), was used to examine the genetic bases of these model auxotrophies (Fig. 4). Based on this analysis, six of the eight *Shigella* strains exhibited an auxotrophy for niacin (vitamin B₃) in silico. These simulation results are consistent with literature data indicating that many strains of *Shigella*, including *Shigella sonnei* Ss046 and *Shigella boydii* sb227, are unable to grow without addition of niacin to M9 minimal media with glucose (29). Gap analysis attributes this auxotrophy to the lack of L-aspartate oxidase activity, encoded by the gene *nadB*, in the nicotinic acid biosynthesis pathway. A bioinformatic analysis of *nadB* suggests that it is a pseudogene due to numerous nonsynonymous mutations compared with the sequence of *nadB* in *E. coli* K-12.

Two additional examples of identifying and confirming strain-specific auxotrophies involved models for *Shigella flexneri* 2a str 301, (auxotrophic for methionine) and *E. coli* strain DH10B (auxotrophic for leucine). Gap analysis of *S. flexneri* 2a str 301 suggested that the auxotrophy is due to the absence of homoserine O-transsuccinylase, encoded by *metA* in *E. coli* K-12 MG1655. A bioinformatics analysis suggested that *metA* is a pseudogene in




Fig. 3. Classification of *E. coli* pathotypes based on growth-supporting conditions. Growth-supporting nutrients were used to create a classification tree. This tree can be used to determine if an *E. coli* strain is commensal, an intestinal pathogen, or an extraintestinal pathogen. For example, following the tree to the right shows that 77% of *E. coli* strains that cannot grow on α -mannosylglycerate, fructoselysine, or taurine as sole carbon sources are expected to be extraintestinal pathogens. Thus, a small number of nutrient sources can be used to classify *E. coli* strains of different types.

Table 1. Nutrients predicted to give commensal strains or extraintestinal pathogenic strains of *E. coli* a catabolic advantage

Source	Commensal (%)	ExPec (%)	P value
ExPec strain nutrients			
3-Phospho-D-glycerate	0	36	1.3E-2
L-Arginine	11	64	5.0E-3
Cellobiose	33	82	1.3E-2
N-acetyl-D-galactosamine	67	100	3.9E-2
Commensal strain nutrients			
Fructoselysine	89	0	2.2E-6
Psiscoselysine	89	0	2.2E-6
Dopamine	89	0	2.2E-6
Phenethylamine	89	0	2.2E-6
Tyramine	89	0	2.2E-6
Phenylacetaldehyde	72	0	1.2E-4
α-Mannosylglycerate	94	9	5.7E-6
4-Hydroxyphenylacetate	56	9	1.3E-2
Cyanate	83	27	3.8E-3
Melibiose	78	27	9.7E-3
Phenylpropanoate	72	27	2.0E-2
3-(3-Hydroxy-phenyl)propionate	89	36	5.0E-3
3-Hydroxycinnamic acid	89	36	5.0E-3

GEM predicted advantages for sole growth-supporting nitrogen and carbon sources between commensal and extraintestinal pathogenic *E. coli* (ExPec) strains. Percentages indicate the portion of each pathotype able to catabolize the listed nutrient source. ExPec strains had a statistically significant capability to catabolize four unique carbon sources compared to commensal strains that overrepresented 13 different sole growth-supporting carbon and nitrogen sources.

S. flexneri 2a str 301 due to single base pair deletion, causing a frameshift mutation at amino acid position 212/310 and hence premature termination of the full-length protein. Both of these

Table 2. Nutrients predicted to give commensal strains or intestinal pathogenic strains of *E. coli* a catabolic advantage

Source	Commensal (%)	InPec (%)	P value
InPec strain nutrients			
Sucrose	33	65	5.0E-2
Raffinose	28	65	2.6E-2
L-Arginine	11	65	1.3E-3
D-Arabitol	0	24	4.6E-2
Ribitol	0	24	4.5E-2
Agmatine	0	47	1.0E-3
Urea	0	47	1.0E-3
Commensal strain nutrients			
Galactonate	100	65	7.6E-3
α-Mannosylglycerate	94	35	2.6E-4
Dopamine	89	41	3.5E-3
Phenethylamine	89	41	3.5E-3
Tyramine	89	41	3.5E-3
5-Dehydro-D-gluconate	78	24	1.6E-3
L-Idonate	78	24	1.6E-3
D-Allose	78	41	2.5E-2
Butyrate	78	47	5.0E-2
Acetoacetate	78	47	5.0E-2
4-Hydroxyphenylacetate	56	18	2.0E-2

GEM predicted advantages for sole growth-supporting nitrogen and carbon sources between commensal and intestinal pathogenic *E. coli* (InPec) strains. Percentages indicate the portion of each pathotype able to catabolize the listed nutrient source. InPec strains had a statistically significant capability to catabolize seven unique carbon and nitrogen sources compared to commensal strains that overrepresented 11 different growth-supporting carbon and nitrogen sources.




Fig. 4. Model predicted strain-specific auxotrophies. GEM predicted minimal media conditions for each auxotrophic strain. *Shigella* strains lack essential vitamin biosynthesis capabilities for niacin (vitamin B3), thiamin (vitamin B1), and folate (vitamin B9). Other strains have lost biosynthetic pathways for the essential amino acids methionine, tryptophan and leucine, thus becoming auxotrophic for these compounds.


observations were confirmed with literature evidence. Specifically, *S. flexneri* strains are known to require methionine (30) in minimal media and *E. coli* DH10B is known to require leucine due to a deletion of the *leuABCD* operon (31).

Experimental Validation of Unique Nutrients Shows High Model Accuracy.

To assess the accuracy of in silico growth simulations, 12 of the 55 reconstructed strains were screened for growth on six carbon sources. Growth was estimated by optical density 48 h after inoculation. OD values of >0.08 were considered growth. The 12 strains consisted of 3 ExPec strains, 3 InPec strains, 5 commensal strains, and 1 *Shigella* strain, thereby spanning the pathotypes discussed above. Six carbon sources were selected based on their predicted ability to classify strains according to different pathotypes. In other words, each of these six substrates was expected to support growth of certain strains but not others. The models are validated by true-positive and true-negative results that highlight cases where the models are in agreement with experimental results. In contrast, false-positive and false-negative cases indicate potential errors or gaps in the models (17) (Fig. 5A). The experimental results showed a high level of accuracy with 80% of GEM predictions agreeing with experiments.

Comparison of in silico and experimental results revealed complete agreement for two different carbon sources: acetoacetate and deoxyribose were predicted correctly with 100% accuracy (8 and 2 true positives, as well as 4 and 10 true negatives, respectively) across all 12 strains (Fig. 5B). Acetoacetate is transported into the cell via a proton symporter encoded by *atoE*. Growth of *E. coli* on SCFAs, such as acetoacetate, requires activation of the acid to its respective thioester (32). For acetoacetate, this activation is catalyzed by acetoacetyl-CoA transferase encoded by *atoA* and *atoD* that form a four unit enzymatic complex. The four strains lacking these two genes were correctly predicted not to grow on acetoacetate as a sole carbon source. Deoxyribose is the second compound predicted with 100% accuracy. It is transported into the cell via a proton symporter encoded by *deoP*. Deoxyribose is then phosphorylated to deoxyribose-5-phosphate by deoxyribose kinase, encoded by *deoK* (33). Finally, deoxyribose-5-phosphate is converted into acetaldehyde and glyceraldehyde-3-phosphate by deoxyribose-phosphate aldolase encoded by *deoC*. Only two of the strains tested, *E. coli* O42 and *E. coli* CFT073, possessed these genes and were correctly predicted by the models to be able to grow on deoxyribose as a sole carbon source. These cases validate the approach and demonstrate high accuracy to discriminate between different strains' capabilities.

A single pathway for two aromatic phenyl compounds, phenylacetaldehyde and phenylethylamine, was responsible for significant differences between model predictions and experimental results. The growth predictions for phenylacetaldehyde and phenylethylamine (tested individually) exhibited identical profiles of seven false negatives and only five true positives during in vivo growth screens (42% accuracy). These two compounds share



B

Compound	Genes	Commensal Strains					Intestinal Pathogens			Extra-intestinal Pathogens			Shigella	Substrate accuracy
		MG1655	8739	DH1	H5	KO11FL	O42	EDL933	Sakai	SMS3-5	CFT073	UMN026	2457T	
Acetoacetate	<i>atoE, atoAD</i>	TP	TP	TP	TP	TN	TP	TN	TN	TP	TP	TP	TN	100%
Deoxyribose	<i>deoC, deoP, deoK</i>	TN	TN	TN	TN	TN	TP	TN	TN	TN	TP	TN	TN	100%
D-malate	<i>dctA, yeaU</i>	TP	TP	TP	FP	TP	TP	TP	TP	TP	FP	TP	TN	83%
Ferric dicitrate	<i>fecBCDE</i>	TP	TP	TP	TN	TN	TP	TN	TN	FN	TN	FP	TN	83%
Melibiose	<i>melA, melB</i>	TP	TP	FP	TP	TP	FN	TP	TP	TP	FN	TP	TP	75%
2x Phenyls	<i>tynA, feaB, paaK</i>	TP	TP	TP	TP	TP	FN	FN	FN	FN	FN	FN	FN	42%
Strain accuracy:		100%	100%	83%	83%	100%	67%	83%	83%	67%	50%	67%	83%	

Fig. 5. Comparison of GEM predictions to experimental results. Comparison of GEM predictions to experimental results revealed a high level of accuracy (80%) both for true positives (quadrant 1) and true negatives (quadrant 4). False negative cases (quadrant 2) represent missing knowledge and are an opportunity for biological discovery. False positive cases (quadrant 3) represent missing context-specific information such as transcriptional regulation. (B) A detailed breakdown of the comparisons based on the pathways (rows) and screened strains (columns).

a catabolic pathway whereby phenylethylamine is converted to phenylacetaldehyde by phenylethylamine oxidase encoded by *tynA* (34). Phenylacetaldehyde dehydrogenase, encoded for by *feaB*, then converts phenylacetaldehyde to phenylacetic acid. The acid is subsequently converted to phenylacetyl-CoA by phenylacetate-CoA ligase encoded by *paaK*. The genes coding for enzymes that catalyze these reactions in *E. coli* K-12 MG1655 had very low identity (<40%) at the amino acid level to genes in strains that proved capable of using these substrates as sole sources of carbon. Therefore, the growth experiments indicate that either these low identity enzymes are carrying out the activity or there is an alternate pathway for catabolism of these two compounds.

Discussion

GEMs of metabolism are powerful tools that can be deployed to investigate similarities and differences between strains of the same species. Unique GEMs for 55 different *E. coli* strains were constructed and used to (i) compare and contrast core and pan metabolic capabilities within the *E. coli* species; (ii) determine functional differences between strains by computing growth phenotypes on more than 650 different nutrients both aerobically and anaerobically; and (iii) explore the genetic basis behind strain-specific auxotrophies. These computational classifications and studies were fortified by performing in vitro screens of select discriminating compounds and strains resulting in a high level of accuracy (80%).

The majority of reactions found in pan metabolism fell into the metabolic subsystem of alternate carbon metabolism. It was hypothesized that these differences give different strains advantages in preferred microenvironmental niches. A clustering analysis based on computed metabolic phenotypes clearly distinguished *E. coli* strains from *Shigella* and largely separated *E. coli* strains known to exhibit a commensal intestinal lifestyle from those known to exhibit both intestinal and extraintestinal pathogenic lifestyles. This separation was based solely on the catabolic capabilities of different strains for unique nutrient sources. A major distinction that appeared was the capability to degrade fructoselysine and psicoselysine, indicating that these compounds may be a defining feature of intestinal *E. coli* strains. This pathway is missing from all extraintestinal *E. coli* strains investigated. One possible mechanism that explains this feature begins with the observation that fructoselysine is poorly digested in the small intestine and absorption occurs only through diffusion (23). As a result, fructoselysine moves to the large intestine

where it is present in abundance. However, excretory levels of fructoselysine are low; thus, it has been postulated that the intestinal microbiota, including *E. coli*, ferment almost all dietary fructoselysine. *E. coli* K-12 MG1655 has been shown to sustain growth on fructoselysine as a sole carbon source in anaerobic environments (23), and 88% of the intestinal strains modeled are predicted to be capable of using fructoselysine or psicoselysine as a sole carbon source.

Another example of strain discrimination was the aromatic compound 4-hydroxyphenylacetic acid that was catabolized by 55% of commensal intestinal strain models compared with 9% of extraintestinal strain models. Hydroxyphenylacetic acids are one of several classes of aromatic compounds produced by bacterial fermentation of short chain peptides and amino acids in the human large intestine (24). Specifically, 3- and 4-hydroxyphenylacetic acid have been identified as products of tyrosine fermentation (34) by the diverse colonic microbiota. Therefore, these compounds are likely present at high levels in the intestine. Thus, utilization of 4-hydroxyphenylacetic acid as a sole carbon source may provide a competitive advantage over other strains of *E. coli* in the gut.

In addition to unique growth capabilities, the GEMs are also able to reliably predict strain-specific auxotrophies. This ability is important as auxotrophies often indicate cases of antagonistic pleiotropy, whereby ancestral traits that interfere with virulence are lost to a newly evolved pathogen. Traits absent in pathogenic strains of a species but commonly expressed in commensal ancestors are strong candidates for pathoadaptive mutations. Evidence of this model of pathogen evolution was first provided by *Shigella* and *E. coli*. Widespread niacin auxotrophies in *Shigella* strains were identified due to disruption of *nadA* and *nadB* genes that code for the enzyme complex that converts L-aspartate to quinolate, a precursor to NAD synthesis. This finding is validated by previous literature confirming that quinolate inhibits invasion and cell-to-cell spread of *Shigella flexneri* 5a. Reintroduction of functional copies of *nadA* and *nadB* into this strain restored the ability to synthesize quinolate but also resulted in strong attenuation of virulence in this strain (35). Therefore, several of the additional auxotrophies identified for other vitamins such as folate and thiamin, as well as amino acids leucine, methionine, and tryptophan, may indicate further cases of antagonistic pleiotropy. Future studies could explore the impact of these auxotrophies on virulence in each strain to potentially elucidate new pathoadaptive mutations.

Growth experiments were performed for six carbon sources tested on 12 different strains to evaluate the accuracy of the

developed models. The overall accuracy of the models was 80%, a level that is in line with predecessor models (12–15). This high level of accuracy is notable because the substrates tested were selected due to their ability to differentiate among strains, making them some of the most difficult compounds to correctly predict. Three of the strains, 8739, HS, and MG1655, had 100% predictive accuracy. These strains are all safe, commensal laboratory strains, which likely contributed to them having better genome annotations and subsequently more accurate model predictions. Cases where the models are incorrect provide opportunities for biological discovery. False positives represent missing context-specific information in a GEM. These cases occur when model-predicted growth on a compound disagrees with the lack of growth observed experimentally. For example, growth on D-malate was a false positive for two models of *E. coli* strains. Even though both strains have a gene that has high identity to the D-malate decarboxylating oxidoreductase enzyme, encoded by *yeaU*, they were unable to grow on this compound. This could indicate a case where expression of this enzyme is transcriptionally repressed. Adaptive laboratory evolution of these two strains on D-malate may relieve the transcriptional repression of *yeaU* and lead to identification of novel regulators involved in controlling the catabolism of this compound (36).

In contrast to false positives, false negatives occur when comparing *in silico* and *in vitro* data to identify missing content in a GEM. Growth predictions for phenylacetaldehyde and phenylethylamine consisted of seven false negatives. These two compounds share the same catabolic pathway. The three genes catalyzing reactions in this pathway for *E. coli* K-12 MG1655 had very low identity (<40%) to genes in strains that proved capable of using these substrates as sole sources of carbon. Therefore, the growth experiments indicate that either a particular domain on these low identity enzymes is carrying out the activity or there is an alternate pathway for catabolism of these two compounds. Further characterization and studies on gene KOs for this pathway in each

strain could lead to identification of a new alternate pathway for phenylacetaldehyde and phenylethylamine catabolism.

The work presented here shows that strain-specific models of *E. coli* can guide further studies regarding the advantages conferred by unique nutrients to *E. coli* strains in different niches. Additionally, the models reliably predict strain-specific auxotrophies documented in the literature, as well as novel auxotrophies that offer a strong case for future study. Taken together, this study represents a step toward the definition of a bacterial species based on common metabolic capabilities and its strains based on niche-specific growth capabilities. In addition to this fundamental advance, the niche-specific characteristics provide a basis for understanding strain and species-specific pathogenesis. Similar studies of diverse strains for species beyond *E. coli* will further define the concept of a species. Ultimately, this understanding can be leveraged to formulate strain- and species-specific drug development and therapeutic approaches.

Materials and Methods

The strain-specific model reconstruction procedure, gap filling algorithms, and *in silico* growth simulation conditions are described in *SI Materials and Methods*. Heatmap and phylogenetic tree and decision tree construction are described in *SI Materials and Methods*. Carbon source and growth testing protocols are described in *SI Materials and Methods*. Eleven strains of *E. coli* and one strain of *S. flexneri* were tested as part of this study. The 11 *E. coli* strains are SMS 3–5; CFT073; HS; DH1; UMN 026; K011; Sakai; ATCC 8739; 042; EDL933; and K-12 MG1655. The *S. flexneri* strain was 2457T. *E. coli* 042 was a gift from Ian Henderson (Birmingham University, Birmingham, UK). All other strains were purchased from ATCC.

ACKNOWLEDGMENTS. We thank Ian Henderson for the gift of *E. coli* strain 042. We thank Kathy Andrews and Donghyuk Kim for assistance with culture and storage of the strains used in this work. Additionally, we thank Aarash Bordbar for helpful discussions and insights. This work was funded by National Institutes of Health/National Institute of General Medical Sciences Grants 1R01GM098105 and 1R01GM057089.

- Hayashi T, et al. (2001) Complete genome sequence of enterohemorrhagic *Escherichia coli* O157:H7 and genomic comparison with a laboratory strain K-12. *DNA Res* 8(1):11–22.
- Perna NT, et al. (2001) Genome sequence of enterohaemorrhagic *Escherichia coli* O157:H7. *Nature* 409(6819):529–533.
- Canchaya C, Proux C, Fournous G, Bruttin A, Brüßow H (2003) Prophage genomics. *Microbiol Mol Biol Rev* 67(2):238–276.
- Touchon M, et al. (2009) Organised genome dynamics in the *Escherichia coli* species results in highly diverse adaptive paths. *PLoS Genet* 5(1):e1000344.
- Liao YC, et al. (2011) An experimentally validated genome-scale metabolic reconstruction of *Klebsiella pneumoniae* MGH 78578, iYL1228. *J Bacteriol* 193(7):1710–1717.
- Baumler DJ, Pepinski RG, Reed JL, Glasner JD, Perna NT (2011) The evolution of metabolic networks of *E. coli*. *BMC Syst Biol* 5:182.
- Archer CT, et al. (2011) The genome sequence of *E. coli* W (ATCC 9637): Comparative genome analysis and an improved genome-scale reconstruction of *E. coli*. *BMC Genomics* 12:9.
- Yoon SH, et al. (2012) Comparative multi-omics systems analysis of *Escherichia coli* strains B and K-12. *Genome Biol* 13(5):R37.
- Charusanti P, et al. (2011) An experimentally-supported genome-scale metabolic network reconstruction for *Yersinia pestis* CO92. *BMC Syst Biol* 5:163.
- Tiele I, et al. (2011) A community effort towards a knowledge-base and mathematical model of the human pathogen *Salmonella* Typhimurium LT2. *BMC Syst Biol* 5:8.
- Blattner FR, et al. (1997) The complete genome sequence of *Escherichia coli* K-12. *Science* 277(5331):1453–1462.
- Edwards JS, Palsson BO (2000) The *Escherichia coli* MG1655 *in silico* metabolic genotype: Its definition, characteristics, and capabilities. *Proc Natl Acad Sci USA* 97(10):5528–5533.
- Reed JL, Vo TD, Schilling CH, Palsson BO (2003) An expanded genome-scale model of *Escherichia coli* K-12 (J1904 GSM/GPR). *Genome Biol* 4(9):R54.
- Feist AM, et al. (2007) A genome-scale metabolic reconstruction for *Escherichia coli* K-12 MG1655 that accounts for 1260 ORFs and thermodynamic information. *Mol Syst Biol* 3:121.
- Orth JD, et al. (2011) A comprehensive genome-scale reconstruction of *Escherichia coli* metabolism—2011. *Mol Syst Biol* 7:535.
- McCloskey D, Palsson BO, Feist AM (2013) Basic and applied uses of genome-scale metabolic network reconstructions of *Escherichia coli*. *Mol Syst Biol* 9:661.
- Feist AM, Palsson BO (2008) The growing scope of applications of genome-scale metabolic reconstructions using *Escherichia coli*. *Nat Biotechnol* 26(6):659–667.
- Lee SY (2009) *Systems Biology and Biotechnology of Escherichia coli* (Springer, New York).
- Pupo GM, Lan R, Reeves PR (2000) Multiple independent origins of *Shigella* clones of *Escherichia coli* and convergent evolution of many of their characteristics. *Proc Natl Acad Sci USA* 97(19):10567–10572.
- DebRoy C, Roberts E, Fratamico PM (2011) Detection of O antigens in *Escherichia coli*. *Anim Health Res Rev* 12(2):169–185.
- Feist AM, Herrgård MJ, Tiele I, Reed JL, Palsson BO (2009) Reconstruction of biochemical networks in microorganisms. *Nat Rev Microbiol* 7(2):129–143.
- Bliven KA, Maurelli AT (2012) Antivirulence genes: Insights into pathogen evolution through gene loss. *Infect Immun* 80(12):4061–4070.
- Erbersdobler HF, Faist V (2001) Metabolic transit of Amadori products. *Nahrung* 45(3):177–181.
- Smith EA, Macfarlane GT (1996) Enumeration of human colonic bacteria producing phenolic and indolic compounds: effects of pH, carbohydrate availability and retention time on dissimilatory aromatic amino acid metabolism. *J Appl Bacteriol* 81(3):288–302.
- Prieto MA, Diaz E, Garcia JL (1996) Molecular characterization of the 4-hydroxyphenylacetate catabolic pathway of *Escherichia coli* W: Engineering a mobile aromatic degradative cluster. *J Bacteriol* 178(1):111–120.
- Karch H, Tarr PI, Bielaszewska M (2005) Enterohaemorrhagic *Escherichia coli* in human medicine. *Int J Med Microbiol* 295(6-7):405–418.
- Nakano M, et al. (2001) Association of the urease gene with enterohemorrhagic *Escherichia coli* strains irrespective of their serogroups. *J Clin Microbiol* 39(12):4541–4543.
- Reed JL, et al. (2006) Systems approach to refining genome annotation. *Proc Natl Acad Sci USA* 103(46):17480–17484.
- Prunier AL, Schuch R, Fernández RE, Maurelli AT (2007) Genetic structure of the *nadA* and *nadB* antivirulence loci in *Shigella* spp. *J Bacteriol* 189(17):6482–6486.
- Zagaglia C, et al. (1991) Virulence plasmids of enteroinvasive *Escherichia coli* and *Shigella flexneri* integrate into a specific site on the host chromosome: Integration greatly reduces expression of plasmid-carried virulence genes. *Infect Immun* 59(3):792–799.
- Durfee T, et al. (2008) The complete genome sequence of *Escherichia coli* DH10B: Insights into the biology of a laboratory workhorse. *J Bacteriol* 190(7):2597–2606.
- Jenkins LS, Nunn WD (1987) Genetic and molecular characterization of the genes involved in short-chain fatty acid degradation in *Escherichia coli*: The *ato* system. *J Bacteriol* 169(1):42–52.
- Bernier-Fébreau C, et al. (2004) Use of deoxyribose by intestinal and extraintestinal pathogenic *Escherichia coli* strains: A metabolic adaptation involved in competitiveness. *Infect Immun* 72(10):6151–6156.
- Díaz E, Ferrández A, Prieto MA, García JL (2001) Biodegradation of aromatic compounds by *Escherichia coli*. *Microbiol Mol Biol Rev* 65(4):523–569.
- Prunier AL, et al. (2007) *nadA* and *nadB* of *Shigella flexneri* 5a are antivirulence loci responsible for the synthesis of quinolinate, a small molecule inhibitor of *Shigella* pathogenicity. *Microbiology* 153(Pt 7):2363–2372.
- Lee DH, Palsson BO (2010) Adaptive evolution of *Escherichia coli* K-12 MG1655 during growth on a Nonnative carbon source, L-1,2-propanediol. *Appl Environ Microbiol* 76(13):4158–4168.